Ontology highlight
ABSTRACT:
SUBMITTER: Rana Z
PROVIDER: S-EPMC7168248 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Rana Zohaib Z Diermeier Sarah S Hanif Muhammad M Rosengren Rhonda J RJ
Biomedicines 20200130 2
Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors such as prostate cancer, despite the overexpression of HDACs in CRPC. Four HDAC inhibitors, vorinostat, pracinostat, panobinostat and romidepsin, underwent phase II clinical trials for prostate cancers ...[more]